We are a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disease. Our lead asset, RPC1063, is being developed as an oral therapy for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD). The goal of our development strategy for RPC1063 is to demonstrate clinically meaningful differentiation versus other available treatments, including a favorable safety profile.
Meet the team »
We are currently enrolling the Phase 2 portion of an accelerated Phase 2/3 study of RPC1063 in RMS. More information about RADIANCE enrolling locations and patient eligibility requirements can be found here.
We are currently enrolling the Phase 2 study of RCP1063 in Ulcerative Colitis. More information about TOUCHSTONE enrolling locations and patient eligibility requirements can be found here.
December 5, 2013
Receptos to Initiate Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis… MORE »
November 26, 2013
Christian Waage Appointed General Counsel of Receptos… MORE »
November 11, 2013
Receptos to Present at 2013 Credit Suisse Healthcare Conference… MORE »
October 30, 2013
Receptos Reports Third Quarter 2013 Financial Results… MORE »